- Home
- KNSA
as 12-20-2024 4:00pm EST
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.7B | IPO Year: | 2018 |
| Target Price: | $36.60 | AVG Volume (30 days): | 290.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.56 - $28.15 | Next Earning Date: | 10-29-2024 |
| Revenue: | $384,098,000 | Revenue Growth: | 54.41% |
| Revenue Growth (this year): | 60.05% | Revenue Growth (next year): | 36.32% |
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Dec 16 '24 | Sell | $20.44 | 23,017 | $470,467.48 | 95,975 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Dec 6 '24 | Sell | $21.33 | 27,829 | $593,997.43 | 22,958 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Dec 3 '24 | Sell | $21.32 | 15,116 | $323,008.80 | 22,958 | |
| Megna Michael R | KNSA | CHIEF ACCOUNTING OFFICER | Nov 27 '24 | Sell | $22.45 | 8,646 | $194,102.70 | 26,528 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 18 '24 | Sell | $21.04 | 17,000 | $357,680.00 | 95,975 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Nov 6 '24 | Sell | $23.00 | 89,561 | $2,059,903.00 | 79,551 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Oct 15 '24 | Sell | $26.87 | 17,000 | $456,790.00 | 95,975 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Sep 23 '24 | Sell | $24.99 | 17,500 | $437,325.00 | 95,975 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring Three High Growth Tech Stocks In The United States
GlobeNewswire
a month ago
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
MT Newswires
a month ago
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $357,680, According to a Recent SEC Filing
Insider Monkey
a month ago
Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?
GlobeNewswire
a month ago
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
Simply Wall St.
2 months ago
Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Simply Wall St.
2 months ago
Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations
Thomson Reuters StreetEvents
2 months ago
Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call
Compare KNSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.